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Abstract 
Background/aims: Hepatic resection in metastatic disease from colorectal cancer offers the best chance in selected cases for long-term 
survival. Neoadjuvant chemotherapy (NACT) has been advocated in some cases initially deemed irresectable, with few reports of the 
efficacy of such a strategy and the influence of the response to chemotherapy on the outcome of radical hepatic resection.
Methodology: Between December 1995 and May 2005, 27 patients with colorectal liver metastases (seven males, 20 females, mean 
age: 58 ± 8 years; range: 40–75) were treated with neoadjuvant chemotherapy. A seven-year survival analysis was performed. 
Chemotherapy included mainly 5-fluorouracil, leucovorin and either oxaliplatin or irinotecan for a median of eight courses. 
Results: A total of 16 patients (59%) had synchronous and 11 (41%) metachronous metastases. During pre-operative chemotherapy, 
tumour regression occurred in ten cases (37%), stable disease in a further ten patients (37%) and progressive disease developed in 
seven cases (26%). The five-year overall survival for NACT responders was 64% and only 15% for non-responders (p=0.044). 
Conclusions: The response to chemotherapy is likely to be a significant prognostic factor affecting survival after liver resection for cure. 
Abbreviations used in the text: NACT: neoadjuvant chemotherapy; SD: stable disease; CT scan: computed tomography; MRI: 
magnetic resonance imaging; IOUS: intra-operative ultrasonography; CUSA: ultrasonic dissector-harmonic scalpel; TARF: radio-
frequency ablation device; CVC: central venous catheter 
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Introduction 
Surgical resection of colorectal liver metastases, where 
possible, still remains the only treatment ensuring long-term 
survival, when margin-free (R0) hepatic resection can result in 
25–35% reported overall five-year survival [1–7]. This contrasts 
with the dismal long-term prognosis either of untreated hepatic 
metastases [8] or even that where conventional chemotherapy 
alone is used [9–11]. Controversy still remains concerning the 
timing of hepatectomy in resectable cases, either as a stage 
delayed or as a synchronous resection [12, 13] as well as the 
neoadjuvant usage of chemotherapy prior to hepatic resection 
particularly if the disease is initially assessed as irresectable 
[14, 15]. 
The perioperative risks of liver resection have been substantially 
reduced in recent years. It is not, however, clear whether 
systemic pre-operative chemotherapy increases the morbidity of 
subsequent surgery through the induction of steatosis, 
sinusoidal congestion and centrilobular necrosis as has been 
reported with fluoropyrimidine analogues [16, 17] or as a result 
of an increased risk of bleeding during surgery where the post-
chemotherapy hepatic parenchyma tends to be more congested 
and friable following intra-arterial therapy [18]. The effects of 
systemic chemotherapy on the liver parenchyma and on the 
post-operative course following resection have been relatively 
poorly assessed in groups of patients where there has been 
considerable heterogeneity of chemotherapeutic agents utilized 
and variation in the types and techniques of liver resections 
performed [19–22]. The present study reports the effects and 
outcome of pre-operative systemic chemotherapy use in a 
consecutive series of 27 patients presenting with colorectal liver 
metastases as an aid and a guide to definitive metastasis 
resection with curative intent. 
 
Methodology 
Between April 1996 and February 2005, 27 consecutive patients 
affected by colorectal liver metastases received systemic 
chemotherapy prior to liver surgery (seven males; 20 females; 
mean overall age: 58 ± 8 years; range: 40–75 years). The 
rationale of this approach relies on the assumption that occult 
micro-metastases may be present and that neoadjuvant 
chemotherapy is likely to improve the performance of a radical 
(R0) liver resection and that metastases initially deemed 
irresectable may be rendered operable for resection with 
curative intent. 
Patients' characteristics 
The relevant clinical data and tumour characteristics are shown 
in Table 1. Liver metastases were synchronous in 16 cases 
(59%) and bilobar in four cases (15%). The median maximal 
diameter of the metastases was 15 mm (range: 5–80 mm). 
Extrahepatic metastases were detected pre-operatively in three 
patients (11%) with all extrahepatic sites being technically 
resectable either sequentially or at the time of the initial liver 
resection. The sites of the extrahepatic tumours were either 
lung (two cases) or the site of the original primary tumour 
resection (one case). 
Neoadjuvant chemotherapy 
The objectives in medical management were different according 
to the initial resectability of the metastases. For unresectable 
patients, chemotherapy was the only means to convert cases 
into a resectable state and was utilized for longer. For 
resectable patients, the first objective of the chemotherapy was 
to provide a time interval before surgery for assessment of the 
tumour biology, to treat potentially occult disease and to avoid 
surgery in those patients with rapidly progressive disease as a 
result of primary resistance to chemotherapy. A second 
objective in these resectable patients was to achieve 
cytoreduction both to limit the extent of liver resection and 
potentially post-operative morbidity as well as to facilitate a 
margin-free R0 liver resection. The median number of cycles of 
pre-operative chemotherapy per patient was eight (range: 2–
12). In ten patients, systemic chemotherapy was continued 
post-operatively for a median of six cycles. 
The response to chemotherapy was evaluated from serial 
imaging studies (thoraco- and abdomino-pelvic CT scan or MRI 
scanning of the abdomen where indicated) and was based on 
the change in tumour diameter according to the World Health 
Organisation criteria [23]. Response was defined as a 50% or 
more decrease in the total tumour size of lesions, with 
stabilization being defined as a less than 50% decrease or a 
less than 25% increase in the total tumour size. Progression 
was classified as a 25% or more increase in the total tumour 
size and/or the appearance of new lesions at any site. When 
more than one treatment regimen was used in the same patient,  
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Table 1: Patients, tumour characteristics and pre-operative chemotherapy 
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the response to the last regimen used pre-operatively was 
considered for analysis. 
Selection for liver resection 
Patients were eligible for hepatic resection when the following 
conditions were met, namely: (1) no co-morbid conditions were 
present precluding liver resection, (2) all malignant liver disease 
was amenable to resection and ablative treatment whilst being 
able to retain at least 30% of non-tumoural liver parenchyma, 
(3) recurrence of the primary tumour was excluded and (4) 
either no non-resectable extrahepatic disease was detected by 
pre-operative serial imaging studies, or where potentially 
resectable extrahepatic tumour was detected, it was not 
considered a contraindication to sequential or synchronous 
surgery. The time interval between the final chemotherapy dose 
and hepatic surgery was usually 2–4 weeks to minimize the risk 
of tumour progression and to reduce perioperative morbidity. 
This approach was adopted in accordance with other similar 
reports [24, 25]. The policy of liver resection attempted a radical 
resection either by anatomic or non-anatomic (wedge) 
resection, sparing the largest amount of liver parenchyma 
possible but providing a tumour-free margin of 1 cm whenever 
feasible. All procedures routinely used intra-operative 
ultrasound (IOUS), an ultrasonic dissector for parenchymal 
transection (CUSA) and a combination of the argon beam and 
bipolar coagulation forceps to reduce intra-operative blood loss. 
The radio-frequency ablation device (TARF) was used in 
combination with conventional surgery to treat non-resectable 
remnant lesions, thus permitting an extension of the indications 
for liver resection in patients who otherwise would not have 
been candidates for surgery. 
Post-operative follow-up 
Patients were followed up one month after surgery and then 
every four months thereafter with evaluation of tumour markers 
(CEA, and CA 19-9 serum levels), liver function tests and by 
hepatic ultrasound. An abdomino-pelvic or thoraco-abdominal 
CT scan was performed every six months during the follow-up. 
In the case of resectable extrahepatic metastasis(es), sites 
were resected 203 months following definitive hepatic surgery, 
using systemic chemotherapy between operations in order to 
prevent tumour progression. 
Analysis of the data  
Overall and disease-free survival probabilities were determined 
by the Kaplan-Meier analysis [26] and compared using the log-
rank test [27]. A multivariate analysis using a Cox model was 
performed to determine independent prognostic factors for 
survival, with p values < 0.05 being considered significant. 
 
Results 
Liver resection was performed following an objective tumour 
response in ten patients (37%), after stabilization in a further ten 
patients (37%) and after tumour progression in seven patients 
(26%). Major liver resections (≥ 2 segments). were all 
performed with curative intent and included two right 
hepatectomies, one left hepatectomy, one extended right 
hepatectomy, four bisegmentectomies, two bisegmentectomies 
plus one segmetectomy and two bisegmentectomies plus a 
wedge resection. For two patients (3%), liver resection was 
combined with a gastrointestinal resection (namely an anterior 
resection of the rectum). Perioperative mortality was nil (30 
days following surgery). Eighteen patients (67%) were 
discharged without complications with one patient (3%) 
undergoing a right hepatectomy having mild post-operative 
reversible liver failure. Among the minor complications in nine 
patients (33%), there were three pleural effusions, two 
abdominal collections, two wound infections and two central 
venous catheter (CVC) infections. All patients underwent 
hepatic resections with curative intent (R0 resections) with no 
evidence of microscopic involvement of the surgical margin. The 
patient and tumour characteristics according to response to pre-
operative chemotherapy regimens utilized are shown in Table 2. 
Outcome 
Following a mean follow-up of 36 months (range: 8–110 
months), 18 patients suffered from recurrence (67%) amongst 
the 27 patients. Liver recurrence was isolated in eight patients 
(30%) and associated with extrahepatic recurrence in four 
cases (15%). Of the 12 patients with hepatic recurrence, two 
underwent a repeat hepatectomy. Of the 25 patients initially free 
of extrahepatic disease, ten subsequently developed 
extrahepatic recurrences (37%). Of these latter four patients 
underwent one or more re-operations for extrahepatic 
recurrence. 
Survival 
The overall survival (OS) of the 27 patients was 93%, 57% and 
34% at one, three and five years, respectively, with a median 
survival of 30 months (Figure 1). At last follow-up, 12 patients
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Table 2: Patient and tumour characteristics according to response to pre-operative chemotherapy 
(44%) had died with disease. Of the 15 patients alive, nine 
(33%) were disease-free and six (22%) were alive with disease 
(two cases of hepatic disease, two with extrahepatic disease 
and two with both sites involved). Univariate analysis was 
performed with survival as an end point for all items concerning 
patient characteristics, data pertaining to the primary tumour 
(location, stage lymph node invasion, adjuvant chemotherapy, 
time interval between colectomy and hepatectomy), pre-
operative chemotherapy (number of courses, number of lines of 
chemotherapy, utilization of chronomodulated therapy, type of 
regimen, response to chemotherapy), liver metastases 
(synchronous, bilobar versus unilobar, number, size, 
respectability, serum CEA and serum CA 19–9, metastatic 
pedicle lymph nodes), concomitant extrahepatic disease 
(location, curative resection) and technique of liver resection 
(utilization of portal embolization, two-stage versus synchronous 
procedures, combined radio-frequency ablation, major 
hepatectomy, anatomic versus non-anatomic resection, curative 
versus non-curative resection, number and size of metastases 
in the specimen, blood units transfused and duration of hospital 
stay). In some of these subgroups, there were very small 
numbers for adequate comparison. 
On univariate analysis, the only significant factor positively 
predicting survival was the response to neoadjuvant 
chemotherapy (64% versus 15% five-year survival for 
responder versus non-responders respectively, p=0.044). This 
effect is shown graphically in Figure 2. The response to
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Figure 1: Survival of 27 patients undergoing liver resection following neoadjuvant chemotherapy for colorectal-cancer liver metastases.
neoadjuvant chemotherapy, the number of metastases and the 
total size of metastases, was matched in a multivariate analysis 
where the response to pre-operative chemotherapy was 
confirmed as the only significant prognostic variable affecting 
survival (HR 4.531; I.C. 1.002-21.204, p=0.05). 
 
Discussion 
This small study shows that liver resection combined with pre- 
and post-operative (sandwich) chemotherapy offers the 
possibility of long-term survival of patients with 
chemoresponsive liver metastases (single/multiple and/or 
initially irresectable) from colorectal cancer. This benefit can be 
obtained only when the disease confined to the liver is 
controlled by chemotherapy prior to completely resectional 
surgery. Tumour progression whilst on pre-operative 
chemotherapy is associated with a poor outcome, even when 
hepatectomy is performed with curative intent. 
This neoadjuvant approach has been reported to be associated 
with prolonged OS by others where it has been used for 
potentially resectable liver lesions, with demonstration of 
progression-free survival advantage over unresected cases 
[28]. It is, however, recognized that the global impact of 
sandwich pre- and post-operative chemotherapy on such 
progression-free survival is relatively low where, as found in our 
study, less than half of the cases resected are disease-free at 
five years [29]. Our approach does, however, appear safe with 
an acceptable morbidity, which is not exacerbated by the use of 
adjuvant chemotherapy [15,17] although post-operative 
hepatotoxicity is somewhat dependent upon the number of 
cycles administered rather than on the type of chemotherapy 
used [25]. Data concerning the hepatotoxicity of systemic 
neoadjuvant chemotherapy are, however, scarce [21] and may
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Figure 2: Survival of neoadjuvant chemotherapy patients—responders versus non-responders.
suggest a role in selected cases for interstitial concomitant 
therapies [30]. 
Available data would suggest that initial perioperative morbidity 
following hepatic resection appears to adversely affect the 
longer-term cancer-specific survival [31] but that medium-term 
health-related quality of life assessment after hepatectomy 
justifies such an aggressive approach [32]. There is no uniform 
policy regarding the role of synchronous over-staged 
hepatectomy in this setting. It would appear that although 
synchronous metastasis resection is safe and has oncologic 
merit, [33, 34] the potential benefit of the neoadjuvant approach 
is to define tumour biology where initial chemo-responsiveness 
selects those cases suitable for metastasis excision. This may 
be particularly evident when the primary tumour is more 
advanced, where overall cancer-specific prognosis is adversely 
affected when > 4 paracolic lymph nodes are involved [13]. 
It should be recognized that complete chemo-responsiveness 
on imaging may frequently be associated both with macroscopic 
and microscopic evidence of residual disease that may account 
for the relatively high incidence of hepatic in-situ recurrence
found in our study as well as by others [35]. Tumour 
progression on chemotherapy is uniformly associated with a 
poor prognosis [36,37], as reported by Adam and colleagues, 
and similar to our study, this was found even when a potentially 
curative R0 hepatectomy was performed [38]. This group also 
noted (unlike our study) that the prognosis of radical 
hepatectomy after neoadjuvant therapy was affected by the 
number of metastases and the pre-operative serum level of CA 
19-9, but similar to our findings, that the type of chemotherapy 
was not significant to the outcome provided that there was a 
therapeutic response. As in our study, others have reported that 
the presence of some types of extrahepatic disease does not 
contraindicate hepatectomy or subsequent excision of 
resectable extrahepatic sites in selected cases [39]. Where 
recurrence is restricted to the liver, as occurred in our study in 
one-third of recurrent cases, this may be amenable to repeat 
hepatic resection [40]. Outcome in this circumstance is 
dependent upon the radicality of re-resection in much the same 
way that it is in the initial resection. 
In this study, the number of nodules was not a contraindication 
to resectional surgery. The five-year survival following such R0
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liver resection was 34% in our cases: data that compare 
favourably with other surgical series reporting three-year and 
five-year survival of 21% [41] and 23%, respectively [33, 42]. 
One question that remains is whether the response to 
chemotherapy in our cases simply identifies patients who have 
a pre-determined favourable prognosis or whether the response 
is able to modify the actual course of the disease. Supporting 
the latter hypothesis, progression was clearly identified as an 
independent adverse prognostic factor of outcome on 
multivariate analysis. Moreover, treating resectable patients with 
neoadjuvant chemotherapy did not lead to non-resectable 
metastases during the course of the study: an effect also 
observed by others [29, 38]. This effect, combined with long-
term survival in some cases initially defined as non-resectable 
which became down-staged by the neoadjuvant approach 
permitting complete resections, argues for the possibility that 
the course of the disease could be altered by such an 
aggressive strategy [24, 43, 44]. 
In conclusion, the response to neoadjuvant chemotherapy plays 
a key role in the potential benefit offered by radical liver 
resection in selected patients with hepatic metastatic disease 
from colorectal cancer. The poor results obtained by surgery in 
patients with tumour progression suggest that control of the 
disease with a modern combination regimen is preferable to 
immediate surgery. This delayed approach awaiting initial 
chemo-responsiveness might also prove to be relatively liver
sparing and better defines those patients who are potentially 
advantaged by a formal hepatic resection as opposed to a 
tailored segmentectomy. Moreover, in those cases where larger 
metastases completely respond in one area of the liver, 
resection of the contralateral lobe may become an operative 
option [35]. This view is corroborated by recent evidence to 
show that the prognosis is adversely affected in those patients 
undergoing synchronous resection of hepatic metastatic 
disease with their primary tumour when the primary is extensive 
(T4), when it is infiltrating adjacent structures and when there 
are multiple hepatic metastases [45]. 
Overall, the data concerning neoadjuvant benefit to radical 
hepatectomy in colorectal hepatic metastatic disease are hard 
to interpret. This is as a result of variable histopathology in the 
liver, differing chemotherapy schedules, varying types of liver 
resections and different ischaemia/reperfusion cycling 
techniques during hepatic parenchymal transection. In this 
setting, it is not surprising that patients with multiple metastases 
tend to have more prolonged chemotherapy exposure, more 
extended resections and larger tumour/remnant liver ratios. 
Resections for hepatic colorectal metastases are increasing in 
incidence [46] and it is expected that the approach towards 
neoadjuvant therapy even for resectable hepatic metastases will 
be modified in the future by the concomitant use of anti-
angiogenic therapy [47] followed by an aggressive 
approach. 
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